Visualization of high-throughput and label-free antibody-polypeptide binding for drug screening based on microarrays and surface plasmon resonance imaging

Development and application of a visual microarray for synchronously detecting H5N1, H7N9 and H9N2 avian influenza virus RNA

The aim of this study was to develop a microarray assay for the simultaneous detection of the H5, H7, H9, N1, N9 and N2 genes of the avian influenza virus (AIV) using a Nanogold-streptavidin and silver-stain-enhanced nucleic acid dot-blot hybridisation system. The conserved sequences of H5 genes from H5N1, H7 genes from H7N9, H9 genes from H9N2, N9 genes from H7N9 and N2 genes from H9N2 AIV were cloned, together with that of N1 obtained commercially, and were used as templates for generating the probes using biotin-labeled primers, which targeted the conserved regions of H5, H7, H9, N1, N9 and N2 genes, respectively. The oligonucleotide probes were diluted using the spotting buffer and ddH₂O, and each probe was then spotted to each specific position on the microarray. The PCR products including biotin-labeled lambda, NP, H5, H7, H9, N1, N9 and N2 were mixed, 200 μL of which was then added to the microarray chamber after denaturing. Following a hybridization incubation at 45℃ for 120 min, the microarray was then incubated with nanogold-streptavidin about 4 μg/mL for 30 min. After the supplementary of 200 μL of silver buffer A and silver buffer B in the chamber, the hybridization results were assessed by direct visualization in the dark at room temperature. The microarray assay was optimized and its specificity, sensitivity and stability were evaluated. The optimal conditions comprised a probe concentration of 50 μmol/L, a hybridization temperature of 45℃ and a hybridization time of 2 h. The optimal concentration of nanogold-streptavidin was 4 μg/mL and the optimal staining time was 7 min. The results of specificity evaluation showed that no cross-binding of the probes with each other and no cross-hybridization with Newcastle disease virus, infectious bronchitis virus and infectious laryngotracheitis virus was observed. The optimized microarray assay was significantly more sensitivity than the reverse-transcription PCR assay. The microarray was available after storing at less 90 d at 4 ℃. The optimized microarray assay was validated on clinical specimens and the results showed that it had over 95.6% correlation with reverse-transcription PCR method. Therefore, the microarray assay could be used for the high throughput detection of AIV infections due to H5N1, H7N9 and H9N2.

Recent Advances in Biosensors Based Nanostructure for Pharmaceutical Analysis

Background:

The development of novel nanostructures for pharmaceutical analysis has received great attention. Biosensors are a class of analytical techniques competent in the rapid quantification of drugs. Recently, the nanostructures have been applied for modification of biosensors.

Objective:

The goal of the present study is to review novel nanostructures for pharmaceutical analysis by biosensors.

Method:

In this review, the application of different biosensors was extensively discussed.

Results:

Biosensors based nanostructures are a powerful alternative to conventional analytical techniques, enabling highly sensitive, real-time, and high-frequency monitoring of drugs without extensive sample preparation. Several examples of their application have been reported.

Conclusion:

The present paper reviews the recent advances on the pharmaceutical analysis of biosensor based nanostructures.

Plasmofluidics for Biosensing and Medical Diagnostics

Plasmofluidics, an extension of optofluidics into the nanoscale regime, merges plasmonics and micro-/nanofluidics for highly integrated and multifunctional lab on a chip. In this chapter, we focus on the applications of plasmofluidics in the versatile manipulation and sensing of biological cell, organelles, molecules, and nanoparticles, which underpin advanced biomedical diagnostics.

Use of hyperspectral imaging for label-free decoding and detection of biomarkers

Detecting the existence of biomarkers is one of the most important issues in molecular diagnosis. This Letter presents a label-free decoding and detection method for biomarker tests based on hyperspectral imaging and interferometry. The decoding and detection results were extracted from a single hyperspectral image with different spectrum-to-thickness reconstructing algorithms, which made the testing procedure extremely fast and simple. The coding capacity of this method is more than 400, and the detection sensitivity can reach 2 ng/mm2 without fluorescent labeling.